O
OncoInsight
NK cell therapy, solid cancer, breast cancer, and blood cancer
About OncoInsight
OncoInsight, a South Korean biotechnology firm established in 2020, is focused on the development of next-generation cell therapies. The company, under the leadership of CEO DeukChae Na, is advancing a pipeline of allogeneic natural killer (NK) cell-based immunotherapies.
These therapies are engineered to target and eliminate cancer cells, with a primary focus on solid tumors and B-cell malignancies. OncoInsight's proprietary platform technology enables the creation of 'off-the-shelf' NK cell products, which are designed to be readily available for a broad patient population. The company's approach aims to overcome the limitations of current cancer treatments by offering a therapy with a potentially improved safety and efficacy profile.
In addition to oncology, OncoInsight is exploring the application of its NK cell technology in the treatment of B-cell-driven autoimmune diseases, such as lupus. By leveraging the unique properties of NK cells, the company seeks to provide a new therapeutic option for patients with these debilitating conditions. The business model is centered on the research, development, and eventual commercialization of these novel cell therapies, targeting a significant unmet need in the global healthcare market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Seoul, South Korea
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 69.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Oncology, Autoimmune, Cell Therapy, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2021 | $21M | $82M | Envestor · SBI Investment Korea · Rico Asset Management | — |
| OtherOther financing | Jan 2021 | $0 | — | WONIK Investment Partners | ↗ |
Growth signals
Latest recorded traffic for OncoInsight is 860 monthly website visits, down 42.7% over the last three months. OncoInsight's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- ENEnvestor
SBI Investment Korea
Rico Asset Management
Other known investors1 additional known investor
WONIK Investment Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OncoInsight on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OncoInsight’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.